Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03733093
Recruitment Status : Recruiting
First Posted : November 7, 2018
Last Update Posted : May 27, 2022
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:


There are many people living with human immunodeficiency virus (HIV) infection in Liberia. Most experts consider HIV an epidemic there. Researchers want to collect health data from Liberians with HIV over several years. This may help HIV prevention and treatment programs in Liberia.


To learn more about how HIV affects people in Liberia.


People with HIV in Liberia


Participants will be screened with a blood sample.

Participants will visit the study clinic about 10 times over 3 years. They will need to return to the clinic after some visits to get test results. The visits will be closer together during the first part of the study and less frequent later.

At each study visit, participants will:

  • Have a brief physical exam
  • Answer questions about how they are feeling and what medicines they are taking
  • Have blood taken from an arm vein by a needle
  • Give urine samples

Participants ages 12 years or older may be asked questions about HIV risk behaviors. These include sex practices and drug use. Participants ages 18 years or older may be asked how their

HIV infection makes them feel emotionally.

Participants may be asked to join a research substudy. This will be about tuberculosis (TB) testing in people with HIV. For this substudy, participants will have a TB skin test. A small amount of liquid will be injected under the skin on the arm.

Participants will return to the clinic a few days later. The test area will be checked. They will get their test results.


Condition or disease

Detailed Description:
Resources for management of HIV-positive individuals are extremely limited in the West African country of Liberia, and many knowledge gaps exist about the nature of the HIV epidemic in this country. While the prevalence is likely low compared to other regions in Sub-Saharan Africa, the burden of disease is likely high given the current state of the Liberian health care system, despite attempts to improve HIV treatment services and coverage. The Ebola epidemic of 2014-2016 created tremendous strain on a health care system already weakened by years of civil strife, and it is suspected that care for many HIV-positive individuals was disrupted by this event. Currently, clinicians do not have regular access to measurements of CD4 levels or viral loads, making management of people living with HIV in Liberia difficult. While there is some access to antiretroviral (ARV) medications through the National AIDS and Sexually Transmitted Infection (STI) Control Program, several details, including the extent of this access and the impact on disease outcomes, remain unknown. This cohort study will examine these basic factors; attempt to characterize major social/demographic, clinical, immunologic, and virologic features of HIV/AIDS; and investigate the course of HIV disease, including rates of hospitalization, frequencies of ARV regimen modifications, and incidence of certain opportunistic diseases, STIs, other co-infections, and non-AIDS comorbidities among those who are enrolled. Study participants will attend periodic study visits over 3 years. Clinical information will be collected, as will blood and urine samples for clinical and research tests. This protocol is not designed to estimate the prevalence of HIV infection; however, it provides a unique opportunity to generate quality data to understand the course and epidemiology of HIV and AIDS in Liberia. It also provides an opportunity to contribute to the quality and impact of HIV prevention, treatment, and care programs in Liberia.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)
Actual Study Start Date : August 22, 2019
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

HIV Positive

Primary Outcome Measures :
  1. Description of disease course [ Time Frame: Months 1,3,6,12,18,24,30,36 ]
    Description of the course of HIV disease in the study population as a whole or by subgroup.

  2. Characteritics of study population [ Time Frame: Baseline ]
    Description of major social/demographic, clinical, immunologic, and virologic characteristics of HIV disease in the study population at baseline.

Secondary Outcome Measures :
  1. ARV Genotypic Resistance Mutations [ Time Frame: 1 year ]
    Determine ARV genotypic resistance mutations within 1 year of study initiation on stored samples from a subset of participants with HIV-1 pVL >1000 copies/mL at baseline (+/- ART) or at other early study timepoints.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
cohort of individuals currently receiving or initiating care for HIV infection in Margibi and Montserrado Counties, Liberia.

Individuals of any age and gender must meet all of the following criteria to be eligible for study participation:

  1. HIV infection confirmed by HIV-1/2 enzyme-linked immunosorbent assay (ELISA) and confirmatory test or positive assay for HIV-1 pVL.
  2. Ability to provide informed consent.
  3. Willingness to allow storage of biological samples for research testing.
  4. Willingness to be followed by a participant tracker.


Individuals meeting the following criterion will be excluded from study participation:

1. Any condition that, in the opinion of the investigator, would compromise the safety of the study subject or staff, or would prevent proper conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03733093

Layout table for location contacts
Contact: Stephen A Migueles, M.D. (301) 496-7090

Layout table for location information
C.H. Rennie Hospital Recruiting
Kakata, Liberia
Contact: Kumblytee Johnson    +2310770185606   
John F. Kennedy (JFK) Medical Center Recruiting
Monrovia, Liberia
Contact: James Moses, M.D.    +231886659910   
Redemption Hospital Recruiting
Monrovia, Liberia
Contact: Mark Kieh    +231886088723   
Duport Road Clinic Recruiting
Paynesville, Liberia
Contact: Dehkontee Gayedyu-Dennis, M.D.    +231886538810   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Principal Investigator: Stephen A Migueles, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID) Identifier: NCT03733093    
Other Study ID Numbers: 999919014
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: May 27, 2022
Last Verified: March 10, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: .De-identified data will be shared

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Opportunistic Diseases
Sexually Transmitted Infection
Natural History
Additional relevant MeSH terms:
Layout table for MeSH terms
Retroviridae Infections
RNA Virus Infections
Virus Diseases